Gynecology Book

http://www.fpnotebook.com/

Alesse

Advertisement

  1. See Also
    1. Oral Contraceptive
    2. Oral Contraceptive Drug Interaction
    3. Oral Contraceptive Selection
    4. Oral Contraceptive Side Effect Management
    5. Oral Contraceptive-Related Uterine Bleeding Management
  2. Preparations (Levonorgestrel / Ethinyl Estradiol)
    1. Alesse (0.1 / 20)
  3. Components
    1. Levonorgestrel 0.1 mg (see preparation above)
    2. Ethinyl Estradiol 20 ug
  4. Effects
    1. Relative Progestational Activity: 0.5 (low)
    2. Estrogenic Activity: 17 (low)
    3. Androgenic Activity: 0.31 (moderate)
  5. Pill associated problems
    1. Indications to switch to Ortho Cyclen
      1. Acne Vulgaris (lower androgen)
      2. Increased Appetite (lower Progestin)
      3. Major Depression provoked (lower Progestin)
      4. Break-through bleed days 1-9 (more Estrogen)
      5. Break-through bleed all of month (more Estrogen)
      6. Menses too light (more Estrogen, less Progestin)
    2. Indications to switch to Loestrin 1/20
      1. Breast Tenderness or engorgement (lower Estrogen)
      2. Headaches (lower Estrogen)
      3. Moodiness (less Estrogen or more Progestin)
      4. Weight gain (less Estrogen or more Progestin)
      5. Libido decreased (more androgen)
      6. Break-through bleed days 10-21 (more Progestin)
      7. Heavy Menses (more Progestin or less Estrogen)
      8. Dysmenorrhea or Menstrual Cramps (more Progestin)
  6. References
    1. Cerel-Suhl (1999) Am Fam Physician 60(7):2073
    2. Speroff (1993) Obstet Gynecol 81:1034
    3. Dickey (1998) Managing Contraceptive Pill Patients

Alesse (C0718340)

ConceptsSteroid (T110) , Pharmacologic Substance (T121) , Hormone (T125)
EnglishAlesse
SourcesNCI, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree